Affini-T Therapeutics

Affini-T is a leading clinical stage precision immunotherapy company targeting oncogenic driver mutations, beginning with KRAS, to develop potentially curative therapies for patients with solid tumors. We are advancing two distinct T Cell Receptor (TCR) based therapeutic modalities encompassing adoptive cellular therapies and bispecific T Cell Engagers, each designed to harness T cell immunity with unprecedented precision and potency against solid tumors. Our most advanced TCR T-cell therapies are built based on state-of-the-art engineering, synthetic biology, and gene editing proprietary platforms overcoming the challenges of addressing solid tumors. Our T Cell therapies have high specificity and the multi-faceted ability to strike and persist within the solid tumors. Building on the world-class innovation inherent in our leadership team, founders and differentiating technologies, we are powered to develop transformational medicines that last.